Longwood Fund

Longwood Fund is a Boston-based venture capital firm specializing in creating and investing in science-based companies that develop novel solutions for significant medical problems. The firm partners with world-class scientific co-founders to identify groundbreaking discoveries that improve patients' lives. As a value-add investor, Longwood Fund supports its companies in driving therapies from the lab to the patient, often taking active roles in building these companies as Co-Founding CEO, CBO, or President.

The firm's investment strategy focuses on biotechnology and healthcare sectors, targeting companies at various stages, including seed, early stage, growth, and late stage. Longwood Fund has a strong track record of advancing over 20 products to the market, working closely with entrepreneurs and management teams to drive clinical progress. The firm has invested in more than 500 companies and has helped businesses raise more than $10 billion through public equity and debt offerings, including more than 125 IPOs on major stock exchanges worldwide.

Longwood Fund's portfolio includes companies such as Newleos, Evommune, Weaver, BBOT, Solu, and Aavantgarde. The firm's principals have co-founded approximately 25 companies, with over 20 launched or marketed drugs and therapies, as well as over two dozen clinical-stage assets, all focused on helping patients in need. Companies founded by Longwood Fund, or its principals prior to the founding of the firm, as lead investor and CEO/CBO include Acceleron, Alnylam, Be Bio, Immunitas, Momenta, Newleos, Pyxis, Sirtris, Solu, TScan, Vertex, and Weaver.

Longwood Fund's mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide but also create significant value for investors. The firm's first fund, Longwood Founders Fund, L.P., was capped at $85 million when it closed in December 2010. Members of the Longwood team have co-founded and run biotechs worth a combined ~$60 billion, holding roles of CEO, Chairperson, and Lead VC. The Longwood partners have founded over 20 biotech companies, which have launched ~20 drugs, and created sustained market caps of over $100 billion.